Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer
The specific scenarios will include men with newly diagnosed localized, locally advanced, post-operative pT3,4 and/or margin + disease in the setting of an undetectable PSA in addition to post-operative or post-radiation PSA recurrence.
This program is designed to meet the interest of radiation oncologist, residents-in-training, medical oncologists, surgeons, nurses, diagnostic radiologists and pathologists.
- Apply the randomized data regarding dose escalation and hormonal therapy to the management of men with newly diagnosed localized prostate cancer
- Apply the randomized data regarding dose escalation and hormonal therapy to the management of men with newly diagnosed locally advanced prostate cancer
- Apply the available data on the management of a rising PSA following primary surgery or radiation therapy
The following people served as the developers of this activity and their disclosures are listed below.
- Anthony D’Amico, MD, PhD, FASTRO, is employed at Brigham and Women’s Hospital and has no financial relationship
- Theodore DeWeese, MD, FASTRO, is employed by Johns Hopkins University and Digital Harmonics and has no financial relationships with a commercial interest.
- Juanita Crook, MD, is employed at British Columbia Cancer Agency and has a leadership position with ASCO and receives research grants and compensation from Abbvie, Breast Microseed, and Ferring.
- Anders Widmark, MD, PhD, is employed at Umeå University and receives compensation from Astellas, Sanofi Oncology,and Progenics.
- Laurence Klotz, MD, FRCS("C"), is employed by Sunnybrook Health Sciences Centre and has no financial relationships with a commercial interest.
Additionally, the Education and CME/MOC Committees had control over the content of this activity:
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.